Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

ClinicalTrials.gov ID: NCT04225871

Public ClinicalTrials.gov record NCT04225871. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Study identification

NCT ID
NCT04225871
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Biopharma SRL
Industry
Enrollment
200 participants

Conditions and interventions

Interventions

  • zilucoplan (RA101495) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 22, 2019
Primary completion
Jul 26, 2026
Completion
Jul 26, 2026
Last update posted
Jul 19, 2026

2019 – 2026

United States locations

U.S. sites
33
U.S. states
24
U.S. cities
32
Facility City State ZIP Site status
Mg0011 41 Mobile Alabama 36604
Mg0011 116 Phoenix Arizona 85028
Mg0011 31 Irvine California 92697
MG0011 4 Los Angeles California 90033
Mg0011 220 Pasadena California 91101
Mg0011 160 San Francisco California 94115
Mg0011 24 New Haven Connecticut 06511
Mg0011 27 Washington D.C. District of Columbia 20052
Mg0011 25 Tampa Florida 33612
Mg0011 135 Augusta Georgia 30912
Mg0011 188 Glenview Illinois 60026-1339
Mg0011 156 Indianapolis Indiana 46202
Mg0011 32 Kansas City Kansas 66160
Mg0011 33 Detroit Michigan 48201
Mg0011 49 East Lansing Michigan 48824
Mg0011 134 Columbia Missouri 65201
Mg0011 117 Las Vegas Nevada 89145
Mg0011 30 Buffalo New York 14202-1102
Mg0011 123 Great Neck New York 11021
Mg0011 23 New York New York 10021
Mg0011 47 New York New York 10029
Mg0011 22 Chapel Hill North Carolina 27599
Mg0011 122 Cleveland Ohio 44195
Mg0011 38 Columbus Ohio 43210
Mg0011 40 Pittsburgh Pennsylvania 15212
Mg0011 128 Charleston South Carolina 29425-8908
Mg0011 28 Cordova Tennessee 38018
Mg0011 131 Austin Texas 78759
Mg0011 19 Dallas Texas 75390
Mg0011 39 Salt Lake City Utah 84105
Mg0011 164 Charlottesville Virginia 22903
Mg0011 154 Seattle Washington 98195
Mg0011 45 Milwaukee Wisconsin 53215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04225871, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 19, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04225871 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →